NCT02375958View on ClinicalTrials.gov

PCA062 in pCAD-positive Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Triple Negative Breast CancerHead & Neck CancerEsophageal Cancer
Interventions
DRUG

PCA062

Trial Locations (7)

20133

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

77030

Novartis Investigative Site, Houston

78229

Novartis Investigative Site, San Antonio

94805

Novartis Investigative Site, Villejuif

169610

Novartis Investigative Site, Singapore

135 8550

Novartis Investigative Site, Koto Ku

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY